Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancerLambertini, Matteoa; Viglietti, Giuliab; de Azambuja, EvandroaCurrent Opinion in Oncology: January 2019 - Volume 31 - Issue 1 - p 43–51 doi: 10.1097/CCO.0000000000000491 BREAST CANCER: Edited by Giuseppe Curigliano Abstract Author InformationAuthors Article MetricsMetrics Purpose of review This manuscript aims at providing an updated overview on the role of adding ovarian function suppression to tamoxifen or an aromatase inhibitor as adjuvant endocrine therapy in premenopausal women with estrogen receptor-positive early breast cancer. Recent findings Until recently, tamoxifen alone was the only recommended adjuvant treatment option for premenopausal women with estrogen receptor-positive disease. However, recent important evidence has contributed to significantly modify the endocrine treatment landscape in this setting. Summary With the only exception of patients with low-risk clinical-pathological features characterized by excellent survival outcomes with tamoxifen alone, the use of ovarian function suppression is to be considered standard of care for most of premenopausal women with estrogen receptor-positive disease. Regarding the choice of its best partner as endocrine agent, the available data suggest that the higher the risk of disease recurrence the larger benefit can be observed with a more profound estrogen deprivation that can be obtained with ovarian function suppression and an aromatase inhibitor as compared to ovarian function suppression and tamoxifen. Despite the significant improvement in our understanding on the role of ovarian function suppression in this setting, several unanswered questions remain and further research efforts are needed in the field. aDepartment of Medicine bBreast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Brussels, Belgium Correspondence to Matteo Lambertini, MD, Institut Jules Bordet, Université Libre de Bruxelles (U.L.B.), Boulevard de Waterloo 121, 1000 Brussels, Belgium. Tel: +32 2 541 3099; e-mail: email@example.com Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.